AbbVie Net Receivables from 2010 to 2025

ABBV Stock  USD 175.65  0.39  0.22%   
AbbVie Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables will likely drop to about 6.8 B in 2025. During the period from 2010 to 2025, AbbVie Net Receivables regression line of quarterly data had mean square error of 3100232.9 T and geometric mean of  6,103,187,751. View All Fundamentals
 
Net Receivables  
First Reported
2011-12-31
Previous Quarter
11.7 B
Current Value
11.5 B
Quarterly Volatility
2.9 B
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.5 B, Interest Expense of 2.7 B or Selling General Administrative of 7.8 B, as well as many indicators such as Price To Sales Ratio of 3.39, Dividend Yield of 0.0289 or PTB Ratio of 17.2. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of AbbVie Inc over the last few years. It is AbbVie's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

AbbVie Net Receivables Regression Statistics

Arithmetic Mean6,678,536,647
Geometric Mean6,103,187,751
Coefficient Of Variation46.00
Mean Deviation2,601,847,059
Median5,384,000,000
Standard Deviation3,071,886,729
Sample Variance9436488.1T
Range9.5B
R-Value0.83
Mean Square Error3100232.9T
R-Squared0.69
Significance0.000062
Slope537,269,952
Total Sum of Squares141547321.2T

AbbVie Net Receivables History

20256.8 B
202412.8 B
202311.2 B
202211.3 B
202110 B
20208.8 B
20195.4 B

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables12.8 B6.8 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.